This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

A Radiation Therapy Oncology Group Study

John R. Jacobs, MD; Thomas F. Pajak, PhD; Jeannie Kinzie, MD; Muhyi Al-Sarraf, MD; Lawrence Davis, MD; Gerald A. Hanks, MD; Irving Weigensberg, MD; Steven Leibel, MD

Arch Otolaryngol Head Neck Surg. 1987;113(2):193-197.

Abstract
• Cisplatin (cis-platinum, 100 mg/m²) and fluorouracil (1000 mg m² d), for 120 hours' infusion every three weeks for three courses, produced a 93% overall response rate and a 54% complete clinical response at the single-institution level. The same combination was tested in the Radiation Therapy Oncology Group to evaluate the effectiveness and feasibility of this combination. An overall response rate of 86% was obtained, with a 38% complete clinical response. Only 27 of 42 patients completed planned surgery. Compliance with chemotherapy and radiation therapy was substantially better. No additional morbidity after surgical resection or postoperative radiation therapy was identified as secondary to the induction chemotherapy. We conclude that the combination of cisplatin and fluorouracil infusion is effective, with high complete clinical response rate in patients with advanced, previously untreated head and neck carcinoma.

(Arch Otolaryngol Head Neck Surg 1987;113:193-197)

Author Affiliations
From the Department of Otolaryngology (Dr Jacobs) and the Division of Medical Oncology (Dr Al-Sarraf), Wayne State University, Harper-Grace Hospitals, Detroit; Department of Radiation Oncology, University of Colorado, Denver (Dr Kinzie); Radiation Therapy Oncology Group Headquarters, Philadelphia (Dr Pajak); Department of Radiation Therapy, Albert Einstein College of Medicine, Bronx, NY (Dr Davis); Sutter Community Hospital, Sacramento, Calif (Dr Hanks); Methodist Hospital, Peoria, Ill (Dr Weigensberg); and Department of Radiation Oncology, University of California at San Francisco (Dr Leibel).

Footnotes
Accepted for publication July 8, 1986.

Read before the International Conference on Head and Neck Cancer, Baltimore, July 27, 1984.

Reprint requests to the American College of Radiology, 925 Chestnut St, Philadelphia, PA 19107 (M. Kaiser).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Survival Results of Neoadjuvant Chemotherapy for Advanced Squamous Cell Carcinoma of the Head and Neck
Kohno et al.
Jpn J Clin Oncol 2000;30:253-258.
ABSTRACT | FULL TEXT  

Sponge-Gel-Supported Histoculture Drug-Response Assay for Head and Neck Cancer: Correlations With Clinical Response to Cisplatin
Robbins et al.
Arch Otolaryngol Head Neck Surg 1994;120:288-292.
ABSTRACT  

Cisplatin, Fluorouracil, and Leucovorin: Increased Toxicity Without Improved Response in Squamous Cell Head and Neck Cancer
Pfister et al.
Arch Otolaryngol Head Neck Surg 1994;120:89-95.
ABSTRACT  

Chemosensitivity and DNA Ploidy in Head and Neck Squamous Cell Carcinomas
Nakashima et al.
Arch Otolaryngol Head Neck Surg 1992;118:1031-1036.
ABSTRACT  

Circulating C1q-Binding Macromolecules and Their Relationship to Radiographic Characteristics of Laryngeal Cancer
Lavedan et al.
Arch Otolaryngol Head Neck Surg 1991;117:292-296.
ABSTRACT  

Prognostic Indicators in Head and Neck Cancer Patients Receiving Combined Therapy
Davis et al.
Arch Otolaryngol Head Neck Surg 1989;115:1443-1446.
ABSTRACT  

Effects of Cisplatin Plus Fluorouracil vs Cisplatin Plus Cytarabine on Head and Neck Squamous Multicellular Tumor Spheroids
Kohno et al.
Arch Otolaryngol Head Neck Surg 1988;114:157-161.
ABSTRACT